Difelikefalin Impurity 26 is a minor structural variant of difelikefalin monitored in synthetic and stability studies. Altered residues provide insight into how small changes affect chromatographic behavior and conformational preferences. Researchers use it to refine analytical separation and structural elucidation protocols. Applications include impurity profiling, process optimization, and peptide-property correlation analysis.
CAT No: Z10-101-202
Synonyms/Alias:1-(L-phenylalanyl-L-phenylalanyl-L-leucyl-D-lysyl)-4-aminopiperidine-4-carboxylic acid
Difelikefalin Impurity 26 is a synthetic peptide-related compound that arises as a process impurity or degradation product during the manufacture or storage of Difelikefalin, a selective kappa-opioid receptor agonist. As an analytically characterized impurity, it holds significant value in pharmaceutical research and quality control environments, particularly in the context of peptide drug development. Its structural similarity to the parent compound enables researchers to investigate critical aspects of peptide stability, degradation pathways, and analytical method performance, making it an essential reference material for laboratories focused on advanced peptide therapeutics.
Analytical method development: Utilization of Difelikefalin Impurity 26 is integral for the validation and optimization of chromatographic and spectrometric assays designed to detect and quantify process-related impurities in peptide-based pharmaceuticals. By serving as a reference standard, it allows researchers to assess the specificity, sensitivity, and robustness of analytical methods, ensuring accurate differentiation between the parent peptide and structurally related impurities. This is particularly important for compliance with stringent regulatory requirements in pharmaceutical manufacturing and for maintaining product consistency.
Impurity profiling and characterization: The availability of this impurity enables in-depth studies of the impurity profile of Difelikefalin active pharmaceutical ingredient (API) and formulated products. Researchers can employ it to elucidate degradation mechanisms, map impurity formation under various stress conditions, and understand the chemical pathways leading to its appearance. Such profiling is essential for comprehensive risk assessment, setting impurity acceptance criteria, and guiding formulation strategies to minimize impurity levels.
Peptide stability studies: Inclusion of Difelikefalin Impurity 26 in forced degradation and stability-indicating studies supports the identification of critical degradation routes for Difelikefalin and related peptides. By monitoring the emergence and concentration of this impurity under different storage, processing, or formulation environments, scientists can gain valuable insights into the factors affecting peptide stability, shelf life, and optimal storage conditions. These findings directly inform the design of robust manufacturing processes and effective formulation approaches.
Reference material for process optimization: In peptide synthesis and purification research, Difelikefalin Impurity 26 serves as a benchmark for evaluating the efficiency of process controls and purification steps. Its presence or absence in intermediate or final products provides a sensitive indicator of process performance, enabling the fine-tuning of synthesis parameters, purification protocols, and in-process monitoring strategies. This contributes to the overall improvement of yield, purity, and quality in peptide manufacturing.
Comparative pharmacological assessment: Although primarily used in analytical and process contexts, the structural similarity of this impurity to Difelikefalin allows for its application in receptor binding or functional assays, where researchers seek to evaluate the biological activity, selectivity, or off-target effects of peptide-related impurities. Such comparative studies are vital for understanding the safety and efficacy implications of low-level impurities in pharmaceutical preparations, supporting comprehensive risk assessments during drug development and quality assurance.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More